Literature DB >> 7577064

European School of Oncology Advisory report to the Commission of the European Communities for the "Europe Against Cancer Programme" cost-effectiveness in cancer care.

C Williams1, D Coyle, A Gray, J Hutton, T Jefferson, G Karlsson, K Kesteloot, C Uyl-de Groot, S Wait.   

Abstract

Entities:  

Mesh：

Year:  1995        PMID： 7577064     DOI： 10.1016/0959-8049(95)00286-r

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  5 in total

1.  Comments on economic evaluation of chemotherapy.

Authors:  S R Clausen; V Jøjnsson; M M Hansen; H Keiding; M Kjaer; B E Christensen; H Mouridsen; T Palshof; S W Hansen
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

Review 2.  A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer.

Authors:  J Hutton; R Brown; M Borowitz; K Abrams; M Rothman; A Shakespeare
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 3.  Pharmacoeconomic considerations in treating patients with acute leukaemia.

Authors:  V Jønsson; M M Hansen; P Ljungman; S Kaasa
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

4.  Economic aspects of treatment for fungal infections in cancer patients.

Authors:  K Torfs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

5.  Health State Utilities for Patients with Brain Metastases.

Authors:  Nataniel H Lester-Coll; Arie P Dosoretz; James A Hayman; James B Yu
Journal:  Cureus       Date:  2016-07-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.